VIVES is a multi-sector fund that invests in projects with a positive societal impact
GreenWatt, founded in Belgium in 2004 as a spin-off from the Catholic University of Louvain (UCLouvain), designs, develops and markets locally integrated "key-to-door" biogas plants for the food and...
Generare is unlocking nature’s untapped potential, turning the complexity of microbial DNA into a scalable platform that can transform drug discovery.
By combining advanced biotechnology with data...
ExeVir is a clinical-stage company developing antiviral therapies using its VHH technology platform to provide broad protection against viral infections, including coronaviruses. The platform builds...
Michel Detheux, CEO iTeos Therapeutics:
"VIVES has played a unique dual role as incubator and spin off investor during the inception of iTeos not only to shape the equity story, but also to connect...
David Frenay, CEO Emolytics:
"Emolytics is a spin-off of the UCLouvain, founded in 2014 and acquired by Profacts in 2018. Emolytics has been supported by VIVES II Fund since its inception, as VIVES...
Philippe Mengal, past CEO Greenwatt:
"The support of VIVES was essential because it was first of all a demonstration of confidence at a very early stage of the company just out of UCL Laboratories...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to